[Experience with a new hydro-soluble contrast medium (author's transl)]

Area of Science:

• Radiology
• Neurology
• Pharmacology

Background:

• Lumbar myelography requires contrast media for imaging.
• Existing contrast agents can cause neurotoxic side effects.
• Patient positioning after myelography impacts tolerability and side effect profiles.

Purpose of the Study:

• To evaluate the tolerability of a new contrast medium, Myelografin.
• To compare the side effect profile of Myelografin with other agents used in lumbar myelography.
• To assess the impact of Myelografin's neurotoxicity on post-examination patient management.

Main Methods:

• Clinical evaluation of Myelografin in patients undergoing lumbar myelography.
• Systematic recording and analysis of adverse events.
• Comparative analysis of side effects against established contrast media.
• Assessment of neurotoxicity through patient outcomes and positioning protocols.

Main Results:

• Myelografin demonstrated very good tolerability in clinical use.
• No spinal or cerebral irritating effects were observed with Myelografin.
• Significantly diminished side effects were noted compared to other contrast media.
• Low neurotoxicity allows immediate patient repositioning to a supine position.

Conclusions:

• Myelografin is a well-tolerated contrast medium for lumbar myelography.
• Its low neurotoxicity profile enhances patient safety and comfort.
• Immediate supine positioning post-examination is feasible, reducing adverse events and improving the overall patient experience.